LUMiC假体在髋臼周围肿瘤缺损重建中的多中心随访研究
该多中心队列研究纳入2008年至2022年间166例因P1b+2、P2、P2+3或P1b+2+3型内半骨盆切除后肿瘤缺损接受LUMiC假体重建的患者,中位随访4.2年。结果显示假体中期耐久性良好,机械性翻修率低,多数患者保留原假体,但再手术风险较高,多数并发症发生于术后早期。
要点
- 166例患者中32例(19%)假体翻修:机械性13例(8%),非机械性19例(11%),主要为假体周围感染15例(9%)。
- 机械性翻修和假体周围感染(Henderson 1至4型)的2年、5年、10年累积发生率分别为11%、18%、24%。
- 同部位既往手术与脱位风险增加相关(HR 3.0),涉及P3区切除与感染风险增加相关(HR 2.5)。
核心结论
- 尽管再手术风险较高,LUMiC假体在中期随访中表现出耐久性,机械性翻修率低,多数患者保留原假体。
- 多数并发症发生于术后最初几个月内。
- 同部位既往手术患者脱位风险增加,或可从更保守的康复和术后护理中获益(作者建议)。
- 作者建议采取措施降低假体周围感染风险,尤其是涉及P3区切除的患者。
研究设计与样本
- 多中心队列研究,纳入2008年至2022年间因P1b+2、P2、P2+3或P1b+2+3型内半骨盆切除后肿瘤缺损接受LUMiC假体重建的患者,共166例,中位随访4.2年(四分位距2.6至7.6年)。
- 并发症按Henderson分类报告,采用竞争风险模型估计机械性和非机械性原因假体翻修及任何并发症再手术的累积发生率,采用Cox模型研究脱位和感染的危险因素。
- 证据等级:治疗性IV级。
主要发现
- 166例中114例(69%)因原发性恶性肿瘤治疗,46例(28%)因转移癌,5例(3%)因良性侵袭性病变,1例(1%)因其他原因。
- 82例(49%)患者共接受165次再手术,其中104次(63%)在6个月内完成。
- 166例假体中32例(19%)翻修:13例(8%)为机械性原因,主要为脱位(5例,3%);19例(11%)为非机械性原因,主要为假体周围感染(15例,9%)。
- 机械性原因翻修和假体周围感染(Henderson 1至4型)在2年、5年、10年的累积发生率分别为11%(95%CI 7%至17%)、18%(95%CI 12%至25%)、24%(95%CI 16%至33%)。
- 同部位既往手术与脱位风险增加相关(病因特异性HR 3.0,95%CI 1.5至6.4;p<0.01),涉及P3区切除与感染风险增加相关(病因特异性HR 2.5,95%CI 1.4至4.7;p<0.01)。
临床怎么用
- 作者认为,同部位既往手术患者脱位风险增加,或可从更保守的康复和术后护理中获益。
- 作者建议,应采取措施降低假体周围感染风险,尤其是涉及P3区切除的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UPDATE: This article was updated on July 17, 2024 because of a previous error, which was discovered after the preliminary version of the article was posted online. The byline that had read "Richard E. Evenhuis, MD 1 , Michiel A.J. van de Sande, MD, PhD 1,2 , Marta Fiocco, PhD 2,3,4 , Demien Broekhuis, MD 1 , Michaël P.A. Bus, MD, PhD 1 , and the LUMiC® Study Group*" now reads "Richard E. Evenhuis, MD 1 , Michiel A.J. van de Sande, MD, PhD 1,2 , Marta Fiocco, PhD 2,3,4 , Edwin F. Dierselhuis, MD, PhD 5 , Demien Broekhuis, MD 1 , Michaël P.A. Bus, MD, PhD 1 , and the LUMiC® Study Group*". The Department of Orthopaedic Surgery, Radboudumc, Nijmegen, The Netherlands, has been added as the affiliation for Edwin F. Dierselhuis, MD, PhD. BACKGROUND: We previously reported promising early results for periacetabular tumor reconstructions using the LUMiC prosthesis. The current study evaluates mid-term complications, revision rates, cumulative incidence of implant revision, and risk factors for complications in a multicenter cohort. METHODS: We assessed patients in whom a tumor defect after type P1b+2, P2, P2+3, or P1b+2+3 internal hemipelvectomy was reconstructed with a LUMiC prosthesis during the period of 2008 to 2022. Complications were reported according to the Henderson classification. Competing risks models were used to estimate the cumulative incidence of implant revision for mechanical and nonmechanical reasons, and reoperations for any complication. Cox models were used to study the effect of risk factors on dislocation and infection. RESULTS: One hundred and sixty-six patients (median follow-up, 4.2 years [interquartile range, 2.6 to 7.6 years]) were included. A total of 114 (69%) were treated for a primary malignant tumor, 46 (28%) for metastatic carcinoma, 5 (3%) for a benign aggressive lesion, and 1 (1%) for another reason. One hundred and sixty-five reoperations were performed in 82 (49%) of the patients; 104 (63%) of the reoperations were within 6 months. Thirty-two (19%) of 166 implants were revised: 13 (8%) for mechanical reasons, mainly dislocation (n = 5, 3%), and 19 (11%) for nonmechanical reasons, mainly periprosthetic joint infection (PJI) (n = 15, 9%). The cumulative incidences of revision for mechanical reasons and PJI (Henderson 1 to 4) at 2, 5, and 10 years were 11% (95% confidence interval [CI], 7% to 17%), 18% (12% to 25%), and 24% (16% to 33%), respectively. Previous surgery at the same site was associated with an increased dislocation risk (cause-specific hazard ratio [HR CS ], 3.0 [95% CI, 1.5 to 6.4]; p < 0.01), and resections involving the P3 region were associated with an increased infection risk (HR CS , 2.5 [95% CI, 1.4 to 4.7]; p < 0.01). CONCLUSIONS: Despite a substantial reoperation risk, the LUMiC prosthesis demonstrated its durability in the mid-term, with a low mechanical revision rate and most patients retaining their primary implant. Most complications occur in the first postoperative months. Patients with previous surgery at the same site had an increased dislocation risk and might benefit from more conservative rehabilitation and aftercare. Measures should be aimed at reducing the PJI risk, especially in resections involving the P3 region. LEVEL OF EVIDENCE: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
引用
- Evenhuis RE, van de Sande MAJ, Fiocco M, et al. LUMiC Endoprosthetic Reconstruction of Periacetabular Tumor Defects: A Multicenter Follow-up Study. J Bone Joint Surg Am. 2024. PMID: 38781319. doi:10.2106/JBJS.23.01082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。